Hienori Toyoda1, Toshifumi Tada2, Philip J Johnson3, Namiki Izumi4, Masumi Kadoya5, Shuichi Kaneko6, Norihiro Kokudo7, Yonson Ku8, Shoji Kubo9, Takashi Kumada2, Yutaka Matsuyama10, Osamu Nakashima11, Michiie Sakamoto12, Tadatoshi Takayama13, Masatoshi Kudo14. 1. Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu, 503-8502, Japan. hmtoyoda@spice.ocn.ne.jp. 2. Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu, 503-8502, Japan. 3. Institute of Translational Medicine, University of Liverpool, Liverpool, UK. 4. Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan. 5. Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan. 6. Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan. 7. Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 8. Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. 9. Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. 10. Department of Biostatics, School of Public Health, University of Tokyo, Tokyo, Japan. 11. Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan. 12. Department of Pathology, Keio University School of Medicine, Tokyo, Japan. 13. Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan. 14. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
Abstract
BACKGROUND: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. METHODS: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. RESULTS: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child-Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. CONCLUSIONS: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.
BACKGROUND: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. METHODS: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. RESULTS: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child-Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. CONCLUSIONS: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.
Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Sarah Berhane; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Chiaki Kagebayashi; Shinji Satomura; Nora Schweitzer; Arndt Vogel; Michael P Manns; Julia Benckert; Thomas Berg; Maria Ebker; Jan Best; Alexander Dechêne; Guido Gerken; Joerg F Schlaak; Arndt Weinmann; Marcus A Wörns; Peter Galle; Winnie Yeo; Frankie Mo; Stephen L Chan; Helen Reeves; Trevor Cox; Philip Johnson Journal: Clin Gastroenterol Hepatol Date: 2016-01-13 Impact factor: 11.382
Authors: R Fox; S Berhane; M Teng; T Cox; T Tada; H Toyoda; T Kumada; C Kagebayashi; S Satomura; P J Johnson Journal: Br J Cancer Date: 2014-04-01 Impact factor: 7.640
Authors: Nicha Wongjarupong; Gabriela M Negron-Ocasio; Roongruedee Chaiteerakij; Benyam D Addissie; Essa A Mohamed; Kristin C Mara; William S Harmsen; J Paul Theobald; Brian E Peters; Joseph G Balsanek; Melissa M Ward; Nasra H Giama; Sudhakar K Venkatesh; Denise M Harnois; Michael R Charlton; Hiroyuki Yamada; Alicia Algeciras-Schimnich; Melissa R Snyder; Terry M Therneau; Lewis R Roberts Journal: World J Gastroenterol Date: 2018-03-28 Impact factor: 5.742